Inflammatory Bowel Disease and the Risk of Extraintestinal Cancers
A team of investigators conducted a systematic review and meta-analysis to assess the risk of extraintestinal cancer in patients with inflammatory bowel disease.
A team of investigators conducted a systematic review and meta-analysis to assess the risk of extraintestinal cancer in patients with inflammatory bowel disease.
Patients who undergo RYGB are less likely to need antihypertensive medications at 3 years compared with those who manage their blood pressure with medical therapy alone.
Is treatment of inflammatory bowel disease (IBD) with biologic therapies harmful during infection with COVID-19?
Treatments guided by metagenomics may result in symptom improvement for patients with irritable bowel syndrome.
Although cannabis use does not induce clinical remission in IBD, patient-reported quality of life may improve.
An AI-powered, fully automated video analysis system may potentially provide endoscopic disease grading in ulcerative colitis that is equal to the scoring of experienced reviewers.
It is unclear if alterations in the intestinal microbiota cause celiac disease, or if the changes are a result of celiac disease.
This study assessed the contribution of the proximal small intestinal microbiota to stunting in an undernourished pediatric population who did not respond to nutritional intervention.
Although further study is required, pilot study results suggest that FMT may be a viable option for patients with IBS with significant bloating.
As the role of the gut microbiome in nonalcoholic fatty liver disease is explored, research has turned to fecal microbiota transplantation as a potential treatment option.